Cereno Scientific strengthens its Scientific Advisory Board with three new members
Cereno Scientific announced today that company is continuing to to strengthen its clinical expertise through the recruitment of three internationally leading experts in cardiology to its Scientific Advisory Board. The new members are Dr Deepak Bhatt, Dr Faiez Zannad and Dr Gunnar Olsson.
“I am pleased to welcome another three top international names to our Scientific Advisory Board, which now gives us access to a very broad base of knowledge. Their solid backgrounds in cardiology will play a central role in our continued work to develop preventive medicine to treat cardiovascular diseases,” says Cereno Scientific’s CEO Sten R. Sörensen.
The purpose of the Scientific Advisory Board is to support the company’s scientific development by recruiting world-leading experts in the company’s focus areas of thrombosis-related cardiovascular diseases. Earlier recruitments to the Scientific Advisory Board include Dr Bertram Pitt and Dr Gordon H. Williams.
Information about the new members:
Deepak Bhatt is a Professor of Medicine at Harvard Medical School and is specialized in cardiovascular medicine and interventional cardiology. Over the years, he has authored 750 scientific articles and is currently Executive Director at Brigham and Women’s Hospital.
Faiez Zannad is a Professor of Therapeutics and Cardiology at the Université de Lorraine and a doctor in medicine and human biology. He has been a leader in the design and implementation of several major international randomized clinical trials, including RALES, VALIANT, EPHESUS and EMPHASIS-HF.
Gunnar Olsson is a licensed physician and Doctor of Medical Science with extensive experience from senior research and development positions in the pharmaceutical industry. He has worked at executive level at AstraZeneca for more that 20 years and has substantial experience of product development and life cycle management. He has also contributed to more than a dozen successful global product registrations, of which seven have achieved so-called “Block buster status” – with annual sales volume exceeding USD 1 billion, for the treatment of both cardiovascular and gastrointestinal diseases.
For further information, please contact:
Sten R. Sörensen – CEO
Tel: +46 733 74 03 74
E-mail: sten.sorensen@cerenoscientific.com
www.cerenoscientific.se
About Cereno Scientific AB
Cereno Scientific is developing a novel preventive medicine to treat thrombosis-related disease, based on the body’s own intelligent clot-busting system. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn, this leads to a high risk of new blood clots. Cereno Scientific’s drug candidate, CS1, is expected to provide a possibility for an effective prevention of thrombosis and a lower risk for serious bleeding complications than with current blood thinning therapies. CS1 is an innovative controlled release formulation of a known compound, and as such is expected to have a relatively short development time. The Gothenburg-based company is located in AstraZeneca’s BioVenture Hub and is supported by GU Ventures. Cereno Scientific’s B share has been listed on Spotlight Stock market since June 2016 with the ticker CRNO B, ISIN SE0008241558.
This information is such that Cereno Scientific AB is required to make public in accordance with the EU’s Market Abuse Regulation (MAR). The information was made public by the Company’s contact person above on April 2, 2019.